Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 11/20 | 0.58 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14532089 | 1.00 | AVPR1A (0.58) | AVPR1AAVPR2ALDH1A1MEN1HTT | |
| SCHEMBL3813359 | 0.91 | LMNA (0.57) | AVPR1AAVPR2ALDH1A1MEN1HTT | |
| SCHEMBL4607419 | 0.91 | ALDH1A1 (0.63) | AVPR1AAVPR2ALDH1A1MEN1HTT | |
| SCHEMBL3813805 | 0.89 | LMNA (0.57) | AVPR1AAVPR2ALDH1A1MEN1HTT | |
| SCHEMBL14531718 | 0.89 | LMNA (0.56) | AVPR1AAVPR2ALDH1A1MEN1HTT | |
| SCHEMBL3818171 | 0.88 | ALDH1A1 (0.55) | AVPR1AAVPR2ALDH1A1MEN1HTT | |
| SCHEMBL3819863 | 0.88 | ALDH1A1 (0.53) | AVPR1AAVPR2ALDH1A1MEN1HTT | |
| SCHEMBL3813718 | 0.88 | ALDH1A1 (0.62) | AVPR1AAVPR2ALDH1A1MEN1HTT | |
| SCHEMBL3813675 | 0.88 | LMNA (0.55) | AVPR1AAVPR2ALDH1A1MEN1HTT | |
| SCHEMBL3809682 | 0.88 | AVPR1A (0.53) | AVPR1AAVPR2ALDH1A1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | claimed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| EP-1948190-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007051810-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD11B2, HSD3B1 | AVPR1A 878/4885AVPR2 861/4885ALDH1A1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.